Description: Eliem Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing novel therapies for neuronal excitability disorders to address unmet needs in chronic pain, psychiatry, epilepsy, and other disorders of the peripheral and central nervous systems in the United States. The company's lead clinical-stage candidates include ETX-810, a novel palmitoylethanolamide prodrug that is in Phase IIa clinical trials for the treatment of diabetic peripheral neuropathic pain and pain associated with lumbosacral radiculopathy; and ETX-155 is a neurosteroid GABAA receptor positive allosteric modulator for the treatment of major depressive disorder, perimenopausal depression, and focal onset seizures. Its lead preclinical program includes Kv7.2/3 potassium channel opener for epilepsy and pain; and novel analog of 2,3- benzodiazepine for the treatment of generalized anxiety disorder. The company was incorporated in 2018 and is headquartered in Redmond, Washington.
Home Page: www.eliemtx.com
ELYM Technical Analysis
23515 NE Novelty Hill Road
Redmond,
WA
98053
United States
Phone:
425 276 2300
Officers
| Name | Title |
|---|---|
| Mr. Robert W. Azelby M.B.A. | Pres, CEO & Director |
| Ms. Erin M. Lavelle | Exec. VP, COO & CFO |
| Dr. Valerie Morisset Ph.D. | Chief Scientific Officer and Exec. VP of R&D |
| Mr. James B. Bucher J.D. | Exec. VP, Gen. Counsel & Sec. |
| Ms. Jo Palmer-Phillips Ph.D. | Chief Devel. Officer |
| Dr. Mark Versavel M.B.A., M.D., MBA, Ph.D. | Interim Chief Medical Officer |
| Ms. Susan Franks M.S. | Sr. VP & Head of Regulatory Affairs |
Exchange: NASDAQ
Country: US
Currency: US Dollar ($)
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 0.4943 |
| Price-to-Sales TTM: | 0 |
| IPO Date: | 2021-08-10 |
| Fiscal Year End: | December |
| Full Time Employees: | 43 |